Erratum: Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1a and STAT-3 (Angiogenesis, (2013) 16, 4, (903-917), 10.1007/s10456-013-9364-7);Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3

Angiogenesis

Volumn 16, Issue 4, 2013, Pages 903-917

  Ganji, Purnachandra Nagaraju ^a   Park, Wungki ^a   Wen, Jing ^a   Mahaseth, Hemchandra ^a   Landry, Jerome ^a   Farris, Alton B ^a   Willingham, Field ^a   Sullivan, Patrick S ^a   Proia, David A ^b   El Hariry, Iman ^b   Taliaferro Smith, Latonia ^a   Diaz, Roberto ^a   El Rayes, Bassel F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Synta Pharmaceuticals Corp   (United States)

Author keywords

Angiogenesis; HIF 1 ; HSP90; STAT 3

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BAG3 PROTEIN; FIBROBLAST GROWTH FACTOR 2; GANETESPIB; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR A; PROTEIN BCL 3; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CASE REPORT; CELL STRAIN HCT116; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECTUM BIOPSY; RECTUM CARCINOMA; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COLLAGEN; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG COMBINATIONS; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LAMININ; MICE, NUDE; PLATELET-DERIVED GROWTH FACTOR; PROTEOGLYCANS; RECTAL NEOPLASMS; RIBONUCLEASE, PANCREATIC; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS; STAT3 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TRIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VESICULAR TRANSPORT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884812874     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-013-9373-6     Document Type: Erratum

References (24)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29. doi: 10.3322/caac.20138
2. Shojaei F (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320(2):130-137
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
4. Joulain F, Van Cutsem E, Iqbal SU, et al. (eds) (2012) Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): mean overall survival (OS) estimation from a phase III trial (VELOUR). ASCO annual meeting, Chicago, IL: JCO
5. Grothey A, Sobrero AF, Siena S, et al. (eds) (2012) Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Gastrointestinal cancer symposium; San Fransisco, CA, JCO
6. Pearl LH, Prodromou C (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75:271-94. Epub 2006/06/08
7. Moser C, Lang SA, Stoeltzing O (2009) Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Anticancer Res 29(6):2031-2042. Epub 2009/06/17
8. Oh SH, Woo JK, Yazici YD, et al. (2007) Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99(12):949-961. Epub 2007/06/15
9. Prinsloo E, Kramer AH, Edkins AL, et al. (2012) STAT-3 interacts directly with Hsp90. IUBMB Life 64(3):266-273. Epub 2012/01/25
10. Proia DA, Foley KP, Korbut T, et al. (2011) Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 6(4):e18552. Epub 2011/05/03
11. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12(2):149-62. Epub 1998/03/07
12. Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107(1):1-3. Epub 2001/10/12
13. Maxwell PH, Dachs GU, Gleadle JM, et al. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94(15):8104-8109. Epub 1997/07/22
14. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. (1999) STAT-3 as an oncogene. Cell 98(3):295-303. Epub 1999/08/24
15. Ying W, Du Z, Sun L, et al. (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11(2):475-484. Epub 2011/12/07
16. Grivennikov S, Karin E, Terzic J, et al. (2009) IL-6 and STAT-3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2):103-113. Epub 2009/02/03
17. Furlan D, Sahnane N, Carnevali I, et al. (2007) Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas. Surg Oncol 16 Suppl 1:S25-S27. Epub 2007/11/21
18. Cho DC, Heath EI, Cleary JM, et al. (eds) (2011) A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report. ASCO annual proceedings, Chicago, IL: J Clin Oncol
19. Proia DA, Sang J, He S, et al. (2012) Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs Epub 2012/01/10
20. Niemisto A, Dunmire V, Yli-Harja O, et al. (2005) Robust quantification of in vitro angiogenesis through image analysis. IEEE Trans Med Imag 24(4):549-553. Epub 2005/04/13
21. Lang SA, Moser C, Gaumann A, et al. (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13(21):6459-6468. Epub 2007/11/03
22. Xu Q, Briggs J, Park S, et al. (2005) Targeting STAT-3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24(36):5552-5560. Epub 2005/07/12
23. Antiangiogenic drugs increase xenograft aggressiveness. Cancer Discov (2012) 2(3):OF3. Epub 2012/05/16
24. Conley SJ, Gheordunescu E, Kakarala P, et al. (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109(8):2784-2789. Epub 2012/02/07